David T.
- Country
- France
- Department
- Pole régionale de cancérologie Service d'Oncologie Médicale
Research Overview
- A Randomized, Open-label, Phase 2 study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investigator’s Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer
- Phase 1 Evaluation of NDI-219216 in Advanced Solid Tumors with/without Microsatellite Instability and Deficient Mismatch Repair
- Sotorasib and Combination Therapy Versus Standard Chemotherapy in Treatment-Naïve Patients with KRAS p.G12C-Mutated Metastatic Colorectal Cancer
Data & Insights
Has run more than one trial at 471 of 728 partner sites.
Specializations
Colorectal Cancer Research
Specializes in investigating novel treatments for metastatic colorectal cancer, with particular focus on HER2-positive tumors and microsatellite instability status. Conducts studies on circulating tumor DNA for treatment decision-making in early-stage disease.
- Liver Metastasis Management
- Immunotherapy Combinations
- Targeted Therapies
Upper GI Cancers
Leads research in gastric cancer, gastroesophageal junction adenocarcinoma, and biliary tract cancers. Focuses on innovative therapeutic approaches including immunotherapy and personalized medicine strategies.
- Advanced Biliary Cancer
- Esophageal Cancer
- Gastric Adenocarcinoma
Pancreatic Cancer
Investigates treatment options for metastatic pancreatic adenocarcinoma, exploring novel therapeutic combinations including immunotherapy agents and chemotherapy protocols.
- First-line Treatment Strategies
- Combination Therapies
- Novel Drug Development
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.